A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression

Hiroko Sugawara,1,2 Kaoru Sakamoto,1 Tsuyoto Harada,3 Satoru Shimizu,4 Jun Ishigooka1 1Department of Psychiatry, Tokyo Women’s Medical University, 2Support Center for Women Health Care Professionals and Researchers, Tokyo Women’s Medical University, Shinjuku-ku, 3Department of P...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sugawara H, Sakamoto K, Harada T, Shimizu S, Ishigooka J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Treatment-resistant depression aripiprazole augmentation predictor Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/2a93f7b213cd419fa1ac95decd76ba59
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2a93f7b213cd419fa1ac95decd76ba59
record_format	dspace
spelling	oai:doaj.org-article:2a93f7b213cd419fa1ac95decd76ba592021-12-02T01:17:33ZA retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression1178-2021https://doaj.org/article/2a93f7b213cd419fa1ac95decd76ba592016-05-01T00:00:00Zhttps://www.dovepress.com/a-retrospective-study-of-predictive-factors-for-effective-aripiprazole-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Hiroko Sugawara,1,2 Kaoru Sakamoto,1 Tsuyoto Harada,3 Satoru Shimizu,4 Jun Ishigooka1 1Department of Psychiatry, Tokyo Women’s Medical University, 2Support Center for Women Health Care Professionals and Researchers, Tokyo Women’s Medical University, Shinjuku-ku, 3Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Arakawa-ku, 4Department of Research, Medical Research Institute, Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan Background: Several studies have evaluated the efficacy and tolerability of aripiprazole for augmentation of antidepressant therapy for treatment-resistant depression (TRD). Here, we investigated the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and bipolar disorder and the clinical predictors of treatment efficacy in a Japanese population.  Methods: Eighty-five depressed Japanese patients who underwent aripiprazole augmentation therapy after failing to respond satisfactorily to antidepressant monotherapy were included in the study. Treatment responses were evaluated based on Clinical Global Impression Improvement scores assessed 8 weeks after initiation of aripiprazole administration. We compared demographic and diagnostic variables, psychiatric medication variables, and clinical variables between remission and nonremission groups.  Results: The aripiprazole augmentation remission rate was 36.5%. Multiple logistic regression analysis indicated that aripiprazole augmentation was significantly more effective for bipolar depression than for major depressive disorder, and both absence of comorbid anxiety disorders and current episode duration >3 months were significantly associated with the efficacy of aripiprazole augmentation.  Conclusion: Polarity of depression, comorbidity of anxiety disorders, and current episode duration may predict the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and bipolar disorder. Among them, comorbidity of anxiety disorders was significantly related to the efficacy for TRD including only major depressive disorder. Additional studies are needed to examine the association between the efficacy of aripiprazole augmentation and bipolarity, and these findings should be validated further in a prospective study. Keywords: TRD, aripiprazole, predictor, bipolar depression, anxiety disorder Sugawara HSakamoto KHarada TShimizu SIshigooka JDove Medical PressarticleTreatment-resistant depressionaripiprazole augmentationpredictorNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2016, Iss Issue 1, Pp 1151-1156 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Treatment-resistant depression aripiprazole augmentation predictor Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Treatment-resistant depression aripiprazole augmentation predictor Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Sugawara H Sakamoto K Harada T Shimizu S Ishigooka J A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
description	Hiroko Sugawara,1,2 Kaoru Sakamoto,1 Tsuyoto Harada,3 Satoru Shimizu,4 Jun Ishigooka1 1Department of Psychiatry, Tokyo Women’s Medical University, 2Support Center for Women Health Care Professionals and Researchers, Tokyo Women’s Medical University, Shinjuku-ku, 3Department of Psychiatry, Tokyo Women’s Medical University Medical Center East, Arakawa-ku, 4Department of Research, Medical Research Institute, Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan Background: Several studies have evaluated the efficacy and tolerability of aripiprazole for augmentation of antidepressant therapy for treatment-resistant depression (TRD). Here, we investigated the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and bipolar disorder and the clinical predictors of treatment efficacy in a Japanese population.  Methods: Eighty-five depressed Japanese patients who underwent aripiprazole augmentation therapy after failing to respond satisfactorily to antidepressant monotherapy were included in the study. Treatment responses were evaluated based on Clinical Global Impression Improvement scores assessed 8 weeks after initiation of aripiprazole administration. We compared demographic and diagnostic variables, psychiatric medication variables, and clinical variables between remission and nonremission groups.  Results: The aripiprazole augmentation remission rate was 36.5%. Multiple logistic regression analysis indicated that aripiprazole augmentation was significantly more effective for bipolar depression than for major depressive disorder, and both absence of comorbid anxiety disorders and current episode duration >3 months were significantly associated with the efficacy of aripiprazole augmentation.  Conclusion: Polarity of depression, comorbidity of anxiety disorders, and current episode duration may predict the efficacy of aripiprazole augmentation for TRD including both major depressive disorder and bipolar disorder. Among them, comorbidity of anxiety disorders was significantly related to the efficacy for TRD including only major depressive disorder. Additional studies are needed to examine the association between the efficacy of aripiprazole augmentation and bipolarity, and these findings should be validated further in a prospective study. Keywords: TRD, aripiprazole, predictor, bipolar depression, anxiety disorder
format	article
author	Sugawara H Sakamoto K Harada T Shimizu S Ishigooka J
author_facet	Sugawara H Sakamoto K Harada T Shimizu S Ishigooka J
author_sort	Sugawara H
title	A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
title_short	A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
title_full	A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
title_fullStr	A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
title_full_unstemmed	A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
title_sort	retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/2a93f7b213cd419fa1ac95decd76ba59
work_keys_str_mv	AT sugawarah aretrospectivestudyofpredictivefactorsforeffectivearipiprazoleaugmentationofantidepressanttherapyintreatmentresistantdepression AT sakamotok aretrospectivestudyofpredictivefactorsforeffectivearipiprazoleaugmentationofantidepressanttherapyintreatmentresistantdepression AT haradat aretrospectivestudyofpredictivefactorsforeffectivearipiprazoleaugmentationofantidepressanttherapyintreatmentresistantdepression AT shimizus aretrospectivestudyofpredictivefactorsforeffectivearipiprazoleaugmentationofantidepressanttherapyintreatmentresistantdepression AT ishigookaj aretrospectivestudyofpredictivefactorsforeffectivearipiprazoleaugmentationofantidepressanttherapyintreatmentresistantdepression AT sugawarah retrospectivestudyofpredictivefactorsforeffectivearipiprazoleaugmentationofantidepressanttherapyintreatmentresistantdepression AT sakamotok retrospectivestudyofpredictivefactorsforeffectivearipiprazoleaugmentationofantidepressanttherapyintreatmentresistantdepression AT haradat retrospectivestudyofpredictivefactorsforeffectivearipiprazoleaugmentationofantidepressanttherapyintreatmentresistantdepression AT shimizus retrospectivestudyofpredictivefactorsforeffectivearipiprazoleaugmentationofantidepressanttherapyintreatmentresistantdepression AT ishigookaj retrospectivestudyofpredictivefactorsforeffectivearipiprazoleaugmentationofantidepressanttherapyintreatmentresistantdepression
_version_	1718403129363398656

A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression

Ejemplares similares